ASXC:NYE-Asensus Surgical Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 0.234

Change

+0.00 (+1.74)%

Market Cap

USD 0.06B

Volume

1.13M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.67 (+0.63%)

USD 185.47B
SYK Stryker Corporation

-1.54 (-0.46%)

USD 133.55B
MDT Medtronic PLC

+0.49 (+0.62%)

USD 112.28B
BSX Boston Scientific Corp

-0.09 (-0.12%)

USD 107.17B
EW Edwards Lifesciences Corp

-1.58 (-1.80%)

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

-0.40 (-0.33%)

USD 26.16B
STE STERIS plc

+2.36 (+1.17%)

USD 21.09B
PHG Koninklijke Philips NV ADR

+0.35 (+1.69%)

USD 18.20B
SNN Smith & Nephew SNATS Inc

+0.57 (+2.39%)

USD 10.70B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 7.94B

ETFs Containing ASXC

MLPA Global X MLP ETF 5.61 % 0.45 %

+0.26 (+0%)

USD 1.60B
AMLP Alerian MLP ETF 5.07 % 0.85 %

+0.16 (+0%)

USD 8.26B
YMLI 4.87 % 0.81 %

N/A

N/A
SIZ 0.32 % 1.71 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.62% 19% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.62% 19% F 3% F
Trailing 12 Months  
Capital Gain -62.86% 10% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.86% 10% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.67% 10% F 2% F
Dividend Return -27.67% 10% F 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.02% 40% F 26% F
Risk Adjusted Return -70.92% 10% F 4% F
Market Capitalization 0.06B 15% F 20% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector